Pharmaceutical - Johnson & Johnson, Antibiotics and Infectious diseases

Filter

Popular Filters

Janssen sets up new group targeting unmet global health needs

Janssen sets up new group targeting unmet global health needs

22-01-2014

US health care giant Johnson & Johnson’s Janssen companies are forming Janssen Global Public Health,…

Anti-viralsAntibiotics and Infectious diseasesJanssenJohnson & JohnsonPharmaceuticalResearch

Four medicines recommended for approval by EMA/CHMP

Four medicines recommended for approval by EMA/CHMP

22-12-2013

Following regular monthly meeting of the European Medicines Agency’s Committee for Medicinal Products…

AlconAntibiotics and Infectious diseasesComtriqDermatologicalsEuropeGaldermaJanssen-CilagJohnson & JohnsonMirvasoNovartisOncologyOphthalmicsPharmaceuticalRegulationSirturoTMC Pharma Services

TAC puts pressure on Janssen finalize development of TB drug bedaquiline

21-11-2013

The current standard of care for multi-drug resistant tuberculosis (MDR-TB) consists of poorly tested…

Antibiotics and Infectious diseasesbedaquilineJanssenJohnson & JohnsonPharmaceuticalPoliticsResearchRest of the World

Rise in infections means hepatitis C market is expected to peak at $15.5 billion in 2022

27-08-2013

The hepatitis C market is forecast to increase by a massive 230% in the next nine years, according to…

AbbVieAntibiotics and Infectious diseasesBristol-Myers SquibbGilead SciencesGlobalJohnson & JohnsonMarkets & MarketingPharmaceuticalsofosbuvir

Pharmstandard to produce Janssen's anti-TB drugs in Russia; Nyuvak deal

24-01-2013

JSC Pharmstandard (PHST: MM), one of Russia's largest pharmaceutical producers, has signed an agreement…

Antibiotics and Infectious diseasesbedaquilineEuropeJanssenJohnson & JohnsonMarkets & MarketingNyuvakOncologyPharmaceuticalPharmstandardProductionquisinostat

Janssen's TB drug Sirturo gains US FDA approval

02-01-2013

The US Food and Drug Administration has granted accelerated approval for US health care major Johnson…

Antibiotics and Infectious diseasesbedaquilineJanssenJohnson & JohnsonNorth AmericaPharmaceuticalRegulationSirturo

Public Citizen urges FDA to reject accelerated approval for Janssen's bedaquiline

27-12-2012

The US Food and Drug Administration should not approve the anti-tuberculosis drug bedaquiline from Janssen,…

Antibiotics and Infectious diseasesbedaquilineJohnson & JohnsonNorth AmericaPharmaceuticalRegulation

FDA staffers seem to back safety of Janssen bedaquiline (Sirturo)

27-11-2012

Ahead of the November 28 meeting of the US Food and Drug Administration's Anti-Infective Drugs Advisory…

Antibiotics and Infectious diseasesbedaquilineJanssenJohnson & JohnsonNorth AmericaPharmaceuticalRegulationRespiratory and PulmonarySirturo

Red tape delaying access to new TB drug in South Africa

20-09-2012

South Africa's drug regulatory authority is placing unreasonable hurdles in the way of desperately ill…

Antibiotics and Infectious diseasesbedaquilineJohnson & JohnsonPharmaceuticalRegulationRest of the World

Janssen-Cilag files for EU approval of bedaquiline in MDR-TB

02-09-2012

Johnson & Johnson (NYSE: JNJ) Belgium-based subsidiary Janssen-Cilag International submitted a Marketing…

Antibiotics and Infectious diseasesbedaquilinedelamanidEuropeJanssen-CilagJohnson & JohnsonOtsukaPharmaceuticalRegulation

News briefs: TB drug developments at Jansen and AstraZeneca; NPS/Amgen deal amended

03-07-2012

US health care giant Johnson & Johnson's (NYSE: JNJ) Janssen Research & Development unit has submitted…

AmgenAntibiotics and Infectious diseasesAstraZenecabedaquilineBiotechnologyCellworkscinacalcetJanssenJohnson & JohnsonLicensingMetabolicsNPS PharmaceuticalsPharmaceuticalRegulationResearch

Back to top